ASH 2025: CAR T cell therapy shows promising Phase II trial results in multiple myeloma

Updated Phase II data for anitocabtagene autoleucel (anito-cel) in 117 relapsed/refractory multiple myeloma patients (median three prior lines) showed a 97% overall response rate and 68% complete response rate; 12- and 18-month progression-free survival were 79% and 66% with overall survival of 95% and 90%, respectively. Safety was manageable with high rates of grade ≥3 cytopenias (66% neutropenia, 24% anemia, 24% thrombocytopenia), mostly low-grade cytokine release syndrome and limited neurotoxicity (nine any-grade, eight grade 1–2); the CAR uses a novel synthetic binder for BCMA and a Phase III head-to-head trial versus standard-of-care is underway (trial supported by Arcellx).

Analysis

Market structure: ACLX (Arcellx) is the clear direct beneficiary—Phase II: ORR 97%, CR 68%, 12/18‑month PFS 79%/66% and OS 95%/90%—which, if sustained, should erode incumbent CAR‑T share in relapsed/refractory myeloma and increase pricing pressure on lower‑efficacy therapies. CDMOs and cell‑therapy supply chain players (e.g., CTLT, LZAGY) stand to gain from higher volume; small bispecific developers are at risk if anito‑cel converts to front‑line use. Expect gradual share shifts over 12–36 months as manufacturing scale and payer contracts are established.

Risk assessment: Near term (days–weeks) the main risks are headline‑driven IV volatility and short covering; short‑term regulatory risk spikes on any AE reports. Material tail risks (low probability/high impact) over 6–24 months include FDA CRL for CMC/manufacturing, IP litigation on the synthetic binder, and reimbursement rejection by CMS leading to >30% revenue downside. Hidden dependencies include third‑party CDMO capacity and CMS/NCD decisions — a manufacturing bottleneck would cap upside even if efficacy is best‑in‑class.

Trade implications: For investors comfortable with biotech idiosyncratic risk, establish a starter long in ACLX (1–2% portfolio) now and scale to 3–5% on pullback ≤‑10% or positive Phase III interim readout; use 12–18 month LEAPS call spreads (20–30% OTM) to control downside. Consider a relative value pair: long ACLX vs short GILD (Gilead) or BMY (Bristol‑Myers) small (0.5–1% net) to express share shift; lengthen exposure to CDMOs (CTLT) by 1–2% for manufacturing capture. Exit/trim if ACLX drops >30% on regulatory setback or Phase III PFS at interim <65%.

Contrarian angles: Consensus likely understates commercialization frictions — superior Phase II safety/efficacy does not guarantee price or penetration; payers may favor bispecifics with outpatient economics. Historical analog: Juno’s early promise derailed by safety/CMC; use that precedent to size positions conservatively and prefer option‑defined exposures. Unintended consequence: best‑in‑class efficacy could create demand >CDMO capacity, delaying revenue and giving incumbents time to defend via price cuts or bundle contracts.

Key Decisions for Investors

• Establish a starter long position in ACLX (Arcellx) equal to 1–2% of portfolio within the next 5 trading days; plan to add to 3–5% on a pullback of ≥10% or on a positive Phase III interim readout (expected within 12–24 months).
• Buy 12–18 month ACLX LEAPS call spread 20–30% OTM (debit spread) to express asymmetric upside while capping premium; size at 0.5–1% of portfolio capital risk.
• Initiate a small pair trade: long ACLX (size above) vs short 0.5–1% position in GILD (Gilead) or BMY (Bristol‑Myers) to capture expected share shift in CAR‑T myeloma over 12–36 months; rebalance if ACLX Phase III PFS <65% at interim.
• Increase exposure to cell‑therapy CDMOs (e.g., CTLT Catalent) by 1–2% to capture manufacturing demand; trim if CTLT reports CDMO capacity expansion that reduces margins or if CMS signals unfavorable reimbursement thresholds.
• Liquidate or cut ACLX exposure by 50% if: (a) FDA issues a complete response letter on CMC within 9–12 months, or (b) Phase III interim PFS <65% or unexpected grade ≥3 neurotoxicity incidence rises above 10% in larger cohorts.